58349-37-4Relevant academic research and scientific papers
TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS
-
Paragraph 00188, (2021/10/30)
The present invention relates to compounds that are Nrf2 activators. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with Nrf2 activation.
New Monodisperse Magnetic Polymer Microspheres Biofunctionalized for Enzyme Catalysis and Bioaffinity Separations
Horak, Daniel,Kucerova, Jana,Korecka, Lucie,Jankovicova, Barbora,Palarcik, Jiri,Mikulasek, Petr,Bilkova, Zuzana
experimental part, p. 647 - 655 (2012/08/08)
Magnetic macroporous PGMA and PHEMA microspheres containing carboxyl groups are synthesized by multi-step swelling and polymerization followed by precipitation of iron oxide inside the pores. The microspheres are characterized by SEM, IR spectroscopy, AAS
Templating a polymer-scaffolded dynamic combinatorial library
Mahon, Clare S.,Jackson, Alexander W.,Murray, Benjamin S.,Fulton, David A.
supporting information; experimental part, p. 7209 - 7211 (2011/09/12)
A water soluble polymer-scaffolded dynamic combinatorial library whose members can interconvert through acylhydrazone exchange was prepared and shown to re-equilibrate in the presence of macromolecular templates.
Supramolecular dendrimers: Unusual mesophases of ionic liquid crystals derived from protonation of DAB dendrimers with facial amphiphilic carboxylic acids
Cook, Andrew G.,Baumeister, Ute,Tschierske, Carsten
, p. 1708 - 1721 (2008/12/20)
Supramolecular liquid crystalline (LC) dendrimers were prepared by self-assembly of first to fifth generation amino terminated DAB dendrimers with facial amphiphilic carboxylic acids. These carboxylic acids are composed of three distinct incompatible segm
PYRROLOPYRIDAZINE DERIVATIVES
-
Page 250, (2008/06/13)
The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-α mediated diseases.
